Pfizer Inc. (NYSE: PFE) reported fourth quarter 2022 earnings results today. Revenues increased 2% year-over-year to $24.3 billion but missed estimates. Reported net income rose 47% to $4.9 billion, or $0.87 per share, compared to the prior year. Adjusted EPS grew 45% YoY to $1.14, beating expectations. For fiscal year 2023, adjusted EPS is expected […]
Pfizer Inc. (NYSE: PFE) reported fourth quarter 2022 earnings results today. Revenues increased 2% year-over-year to $24.3 billion but missed estimates. Reported net income rose 47% to $4.9 billion, or $0.87 per share, compared to the prior year. Adjusted EPS grew 45% YoY to $1.14, beating expectations. For fiscal year 2023, adjusted EPS is expected […]
Pfizer Inc. (NYSE: PFE) reported fourth quarter 2022 earnings results today.
Revenues increased 2% year-over-year to $24.3 billion but missed estimates.
Reported net income rose 47% to $4.9 billion, or $0.87 per share, compared to the prior year. Adjusted EPS grew 45% YoY to $1.14, beating expectations.
For fiscal year 2023, adjusted EPS is expected to be $3.25-3.45.
